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Abstract. Obesity and overweight, well known risk factors for cardiovascular disease and type 2 diabetes, are now associated
with Alzheimer’s disease (AD). It remains to be determined if obesity and overweight contribute to the risk of developing AD
through modulating levels of amyloid-beta (Aβ), a key molecule in AD pathogenesis. Thus, we investigated whether there were
any associations between plasma Aβ levels and body mass index (BMI) or fat mass (FM) in a group of 18 healthy adults. A
statistically signiﬁcant correlation was found between BMI, FM, and plasma levels of Aβ42 (BMI r =0 .602, P =0 .008;F M
r =0 .547, P =0 .019), the longer, more pathogenic form of Aβ, but not with plasma levels of the shorter, less pathogenic Aβ40.
Although not signiﬁcant, positive correlations between plasma levels of Aβ42 and levels of insulin and the inﬂammatory marker
C-reactive protein (CRP), along with an inverse trend between plasma Aβ42 levels and levels of high density lipoprotein (HDL)
were answered. These results suggest that proteins implicated in inﬂammation, cardiovascular disease and type 2 diabetes, which
in turn are riskfactors for AD,may contribute to the associations between BMI/FMand plasma Aβ42 levels. Longitudinal studies
involving larger cohorts are required to determine if elevated body fat may predispose individuals to AD through increasing Aβ42
levels throughout early to late adulthood.
Keywords: Abbreviations: AD, Alzheimer’s disease; Aβ, amyloid-beta protein; APOEε4, Apolipoprotein E epsilon 4 allele;
BMI, body mass index; CRP, C- reactive protein; FM, Fat Mass; HDL, High density lipoprotein; IL, interleukin; LDL, Low
density Lipoprotein; TNFα/β, tumour necrosis factor alpha or beta.
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1. Introduction
The prevalence of overweight and obesity contin-
ues to increase in western societies at an alarming rate
which may be attributed to high saturated fat diets and
physical inactivity. In Australia, for example, almost
60% of men and women are overweight or obese with
the prevalencealmost doublingin the past 20years [7].
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Overweightisdeﬁnedasabodyweightthatexceedsthe
normal or standard weight based on height and frame
sizeandobesityreferstotheconditionofhavingexcess
amount of body fat. An individual can be classiﬁed as
normalweight, overweightandclassiﬁcation I, II or III
obesity.
The most prominent risk factors associated with
overweight and obesity are type 2 diabetes and cardio-
vascular disease, which are in turn themselves, well
known risk factors for Alzheimer’s disease (AD) [27,
58]. In overweight and obese individuals, insulin
clearance is reduced [3,71] contributing to hyperin-
sulinaemia, a condition that has been associated with
an increased risk of developing AD [39,45]. The
cardiovascular risk factors, including high levels of
plasma cholesterol, low density lipoprotein (LDL) and
low plasma levels of high density lipoprotein (HDL)
have all been shown to increase the risk of develop-
ing AD [36,56]. Interestingly some of these factors,
including low HDL levels have also been reported in
patients with type- 2 diabetes in the form of diabetic
dyslipidemia (reviewed in [35]), providing further ev-
idence for a close association between cardiovascular
disease, diabetes and AD.
These risk factors appear to be exacerbated in indi-
viduals carrying the apolipoprotein E4 (APOE ε4) al-
lele such that they have an increased risk of develop-
ing type – 2 diabetes, hypertension, hypercholestero-
laemia,cardiovasculardiseaseandAlzheimer’sdisease
(reviewed in [6,42]). This increase risk in APOE ε4
carriers maybe partly attributed to diet. It has been
reported that a higher intake of calories and fats may
be associated with increased risk of AD in individu-
als carrying this allele [44]. Furthermore, individuals
with type – 2 diabetes possessing the APOE ε4 allele,
are at twice the risk of developing AD compared to ε4
carriers who do not have diabetes [60].
Another link between obesity, cardiovascular dis-
ease, type-2 diabetes and AD may be through inﬂam-
matory processes. Several studies have suggested that
inﬂammation may be associated with hyperinsuline-
mia, insulin resistance, atherosclerosis and AD. Ele-
vatedlevelsoftheC-reactiveprotein(CRP), a sensitive
and stable marker of inﬂammation[63], has been asso-
ciated with increased body mass index (BMI; a mea-
sure of obesity), serum lipids (indicator of cardiovas-
cular disease risk) and increased fasting glucose levels
(indication of diabetes) [10,17,25,30,34,70]. In AD,
an inﬂammatory state with altered cytokine produc-
tion has been well characterised, and associations be-
tween AD risk andfunctionalcytokinepolymorphisms
have also been demonstrated. Such markers include,
interleukin-1 (IL-1) [22], interleukin-6 (IL-6) [72,76],
tumour necrosis factor alpha (TNF-α) [16] and trans-
forming growth factor- β (TGF-β) [8,68,79]. Further-
more, cytokines are present in senile plaques, a neu-
ropathological hallmark of AD [28]. These ﬁndings
suggest that inﬂammation has a key role in AD patho-
genesis that may be exacerbatedbyobesity, diabetes or
cardiovascular disease.
The strongest support for the recent link between
overweight,obesityandADwasprovidedbyGustafson
and colleagues [23], who performed a longitudinal
study examiningthe relationshipbetween BMI and the
subsequent risk of AD. Non-demented Swedish adults
(n = 392) were recruited at age 70 and were followed
through to age 88. The authors found a signiﬁcant
association between BMI and AD in women and not
men. Those women who developed AD through the
agesof79–88hadasigniﬁcantlyhigherBMI thanaged
matched controls. While it does seem that overweight
andobesity appearto be risk factors fordementia,their
role in AD pathogenesis remains unclear.
A key molecule in AD pathogenesis is the amyloid-
beta(Aβ)protein. Thismoleculeiscentraltothe“amy-
loid hypothesis” in which the increased production of
Aβ resultsinneurodegenerationandultimatelydemen-
tia througha cascade of events(reviewedin [73]). Fur-
thermore, increased plasma levels of this protein have
been associated with the increased risk of developing
ADintheelderly[46,47,50]. Itisconceivablethatover-
weight and obesity may directly or indirectly, through
its associated cardiovascular and diabetes risk factors
or inﬂammatoryprocesses, contribute to increased risk
of AD by altering the levels of Aβ. To date there
hasbeennoinvestigationinto whetherdirectindicators
of obesity and overweight, such as BMI, body weight
and percentage fat mass (FM), are associated with al-
tered plasma Aβ levels. Thus, we sought to investi-
gate if there was any relationship between BMI, FM
and plasma Aβ levels in a small cohort of 18 adults.
We found a signiﬁcant correlation between the direct
measures of obesity, (BMI and FM) and plasma levels
of the longer more pathological form of Aβ,A β42.
This study suggests that overweight and obesity may
contributeto the risk of developingAD, by modulating
plasma Aβ42 levels.
2. Materials and methods
2.1. Subjects
For this investigation, 18 healthy adults comprising
of 10 males and 8 females between the ages of 23 andK. Balakrishnan et al. / Body Fat and analysis of plasma amyloid-beta levels 271
Table 1
Measurements and descriptive statistics for Age, levels of total cholesterol, HDL, LDL, triglycerides (Tg), CRP, Insulin, Aβ40
and Aβ42 and BMI and FM (n =1 8 )
Sample Age Cholesterol Tg HDL LDL CRP Insulin BMI FM Aβ40 Aβ42
(Yrs) (mM) (mM) (mM) (mM) (mg/L) (mU/L) (kg/m.m) (Kg) (pg/ml) (pg/ml)
1 27 6.3 3.7 1.2 3.4 2.3 3.7 29.3 31.7 99.9 36.5
2 26 6.9 1.1 1.5 4.9 0.2 3.6 22.6 15.6 131.5 25.5
3 52 7.3 1.5 1.3 5.3 0.5 4.3 22.2 15.6 145.2 17.0
4 31 5.1 1.6 1.0 3.4 3.7 9.9 33.0 37.7 177.5 55.5
5 29 5.4 3.0 0.9 3.1 1.8 8.8 30.0 24.3 190.2 28.5
6 23 4.1 0.7 1.3 2.5 0.4 2.7 19.3 11.8 182.1 21.0
7 40 4.9 1.9 0.9 3.2 0.8 7.5 25.3 19.8 117.9 9.0
8 23 4.8 2.2 1.0 2.8 0.2 5 21.5 9.2 163.8 48.0
9 54 5.8 1.7 1.4 3.7 0.8 7.6 23.8 18.9 201.86 33.0
10 23 4.6 0.5 1.8 2.6 0.4 4.8 21.8 10.1 128.0 19.0
11 29 4.5 0.9 1 3.1 0.6 7.4 23.3 13.0 140.8 2.5
12 64 4.5 0.5 2.4 1.8 0.6 1.5 20.5 14.4 172.8 5.5
13 29 4.4 0.9 1.8 2.2 0.2 2.1 18.7 4.4 123.1 9.9
14 52 7.7 5.31 1.0 N/A 0.6 7.7 26.0 20.9 109.4 15.0
15 23 3.9 0.7 1.3 2.3 0.4 3.7 20.1 16.7 150.4 41.00
16 26 5.9 1.5 1.1 4.1 1.3 4.3 25.4 25.7 113.8 48.5
17 58 6.4 2 0.9 4.5 0.3 10.5 28.3 25.4 231.8 62.0
18 47 4 1.1 1.0 2.4 2.1 18.9 30.9 36.6 47.5 46.0
Descriptive statistics
Min 23 3.9 0.5 0.9 1.8 0.2 1.5 15.6 4.2 47.5 2.5
Max 64 7.7 5.3 2.5 5.3 3.7 18.9 30.9 38.2 231.8 62.0
Mean 36 5.4 1.7 1.3 3.3 1.0 6.3 24.6 20.0 146.0 29.1
SD 14 1.2 1.2 0.4 1.0 0.9 4.1 3.9 10.0 43.3 18.1
Median 29 5.0 1.5 1.1 3.2 0.6 4.9 24.3 19.2 143.0 27.0
IQR 26 1.8 1.1 0.4 1.4 0.9 4.0 5.5 45.5 59.6 31.0
SD – standard deviation, IQR – inter quartile ratio, BMI – body mass index.
64 (mean age 36.4) provided written consent to partic-
ipate in this study. Ethics approval was provided by
HollywoodPrivateHospitalHumanEthicsCommittee.
BMI,andFMwas estimatedforallparticipantspriorto
blood collection between the hours of 0800 and 0900
after subjects have fasted overnight. Participants were
alsoaskedtoavoidvigorousphysicalactivitywithin12
hoursof the assessment. As bioelectricalimpedanceto
measureFMdirectlydependsonbodywatercontentfor
its calculation [32], participants were asked to abstain
fromdrinking3–4hoursbeforetheassessment, abstain
from alcohol consumption and ingestion of diuretics,
including caffeine, 48 hours prior to the assessment.
2.2. Measurement of body mass index and fat mass
Bodymass was measuredthroughthe useofan elec-
tronicscale (UM-018,TanitaCorporation,Japan). Par-
ticipants were instructed to wear light clothing to min-
imise error. Height was measured through the use of
a wall chart and the BMI (kg/m2) was calculated by
dividing mass (kg) by the height squared (m2). FM
was determinedby using the same scale as used for the
mass measurement, which measures percentage body
fat based on the bioelectrical impedance, age, sex and
height of each subject. FM (kg) was calculated as
the product of body mass (kg) and percentage body
fat. Normal weights, overweight and different stages
of obesity were classiﬁed according to the following:
Healthyweight; BMI=18.5−24.9,Overweight;BMI
= 25.0 − 29.9; Obesity; Stage I – BMI = 30.0 − 34.9,
Stage II – BMI = 35.0 − 39.9, Stage III – BMI = >
40.0 [14,15,55].
2.3. Blood collection and analysis
Blood samples were collected using standard veni-
puncture techniques into serum, EDTA and heparin
blood collection tubes (Interpath services, Australia)
containing Prostaglandin E to prevent platelet activa-
tion. Plasma and serum from the blood samples were
separated by centrifugation at 130 g, aliquoted and
stored at −20◦C. Plasma Aβ40 and Aβ42 levels were
determined using a double antibody sandwich enzyme
immunosorbent (ELISA) as previously described [49,
54]. Measurement of other parameters including lev-
els of insulin, CRP, cholesterol, triglycerides, HDL,
and LDL was performed by the Clinical Biochemistry
department, Path Centre (Perth, Western Australia).
Insulin (normal range 6–20 mU/L) was measured on272 K. Balakrishnan et al. / Body Fat and analysis of plasma amyloid-beta levels
Table 2
Multiple Linear Regression of FM, Age, Sex, and APOE ε 4 Status
on Plasma Aβ40 Levels
Variable Unstandardised p-value
β Std. error
Age 0.844 0.817 0.321
Sex 11.150 23.687 0.646
APOE e4 21.703 24.150 0.385
FM −0.465 1.317 0.730
Age, female sex, presence of an APOE ε 4 allele, and fat mass (FM)
were all included in a multiple linear regression analysis on plasma
Aβ40 levels. Signiﬁcance* was deﬁned as p<0.05.
Table 3
Multiple Linear Regression of BMI, Age, Sex, and APOE ε 4 Status
on Plasma Aβ40 Levels
Variable Unstandardised p-value
β Std. error
Age 0.790 0.823 0.354
Sex 15.318 27.016 0.580
APOE e4 23.715 23.705 0.335
BMI 0.399 3.201 0.903
Age, female sex, presence of an APOE ε 4 allele and Body Mass
Index(BMI)were all included inamultiple linear regression analysis
on plasma Aβ40 levels. Signiﬁcance* was deﬁned as p<0.05.
a Tosoh A1A-600 immunoassay analyzer using a 2-
site immunoenzymometric assay. Total cholesterol
(normal range 2.9–5.5 mM), HDL cholesterol (nor-
mal range 1.0–2.9 mM), and triglyceride levels (nor-
mal range 0.2–2.0 mM) were determined enzymati-
cally using a Hitachi 917 autoanalyzer (Roche Diag-
nostics, Sydney). LDL cholesterol was calculated us-
ing the Friedewald calculation [19]; normal range 1.7–
3.5 mM). Plasma CRP levels was measured using the
immunoturbidometirc method using RANDOX CRP
kits, (UK; normal range <10 mg/ml).
Leukocytes were collected for DNA extraction
as previously described [41,65]. Apolipoprotein E
(APOE) genotyping was performed by PCR ampliﬁ-
cation of genomic DNA using the protocol detailed
by Hixson and Vernier [26] and with oligonucleotide
primers described by Wenham and colleagues [77].
2.4. Data analysis
Toinitiallyexploretherelationshipbetweenvariable
sets, scattergram plots were created using Microsoft
Excel (2000) (Microsoft Corporation). Where a re-
lationship was observed, SPSS Version 11.5.0 (SPSS
Inc) was used to verify the statistical signiﬁcance of
the association. Simple linear regression was initially
used, and then multiple linear regression was used to
control for covariates. Associations were considered
Table 4
Multiple Linear Regression of FM, Age, Sex, and APOE ε 4 Status
on Plasma Aβ42 Levels
Variable Unstandardised p-value
β Std. error
Age −0.289 0.269 0.302
Sex 10.857 7.802 0.187
APOE ε 4 0.124 7.955 0.988
FM 1.471 0.434 0.005*
Age, female sex, presence of an APOE ε 4 allele, and fat mass (FM)
were all included in a multiple linear regression analysis on plasma
Aβ42 levels. Signiﬁcance* was deﬁned as p<0.05.
signiﬁcant if linear regression provided a p-value of
less than 0.05.
3. Results
A study was performed in a group of 18 healthy
adults to investigate if there was any association be-
tween body mass index (BMI) or fat mass (FM) and
plasma Aβ40 or Aβ42 levels. Of the 18 subjects
(10maleand8female),8werefoundtocarryanAPOE
ε4 allele (48%). The levels and descriptive statistics
for age, total cholesterol, HDL, LDL, insulin CRP and
insulinlevels,FM,BMI,plasmaAβ40andAβ42levels
for the 18 subjects are presented in Table 1. The data
from this study followed a normal distribution where
the mean age of the participants was 36 years, and
BMI values ranged from 18.7 kg/m2 (healthy weight)
to 33.0 kg/m2 (obese – stage I obesity).
3.1. Plasma Aβ40 levels was not correlated with
either FM or BMI
Linear regression was used to explore the relation-
ship between plasma Aβ40 level and FM or BMI. No
signiﬁcantcorrelationbetweenplasmaAβ40levelsand
either FM (r = −0.183, β =0 .855, P =0 .466,
Fig. 1A) or BMI (r = −0.099, β = −1.014, P =
0.696, Fig. 1B). Separately, age, sex and APOE ε4
genotypewereexaminedbylinearregressioninrelation
to plasma Aβ40 levels. None of these co-variateswere
associated with plasma Aβ40 levels (data not shown).
To further control for these covariates, multiple linear
regression was used, and FM or BMI, age, sex and the
presence of the APOE ε 4 allele were then all included
in the regression model on Aβ40. However, with the
inclusion of these covariates, neither FM nor BMI had
a signiﬁcant effect on plasma Aβ40 levels (Tables 2
and3). Overallthese resultsindicatethatnosigniﬁcant
association between plasma Aβ40 levels and BMI or
FM was observed in our cohort.K. Balakrishnan et al. / Body Fat and analysis of plasma amyloid-beta levels 273
Fig.1. Nocorrelation between FM,BMI,and plasma Aβ40 levels A)Scattergram plot with trendline offat massvsplasma Aβ40levels, (n =1 8 ,
r = −0.183, β =0 .855, P =0 .466. B) Scattergram plot with trendline of body mass index vs plasma Aβ40 levels (n =1 8 , r = −0.099,
β = −1.014, P =0 .696).
3.2. Plasma Aβ42 levels were positively correlated
with both FM and BMI
Following linear regression analysis, a signiﬁcant
positive correlation was found between plasma levels
of Aβ42 for both FM (r =0 .602, β =1 .176, P =
0.008, Fig. 2A) and BMI (r =0 .547, β =2 .349,
P =0 .019, Fig. 2B). Age, sex and the presence of
the APOE ε4 allele were then separately examined in
relation to plasma Aβ42 levels, but these covariates
were not signiﬁcantly associated with altered Aβ42
levels (data not shown). To further control for these
covariates,multiplelinearregressionwasused,andFM
or BMI, age, sex and the presence of the APOE ε 4
allele were thenall includedin the regressionmodelon
Aβ42. The association between plasma Aβ42 levels
and both FM and BMI remained signiﬁcant (Tables 4
and 5). The β-coefﬁcient in Tables 4 and 5 indicate
that for every 1 unit increase in FM or BMI there was
anincreaseof1.471pg/mland3.75pg/mlrespectively,
in plasma Aβ42 levels.
3.3. Association between insulin and plasma levels of
Aβ42
As type – 2 diabetes mellitus has been established as
a risk factor for AD, it was investigated as to whether
therewas anassociationbetweenplasmainsulinlevels,
and plasma Aβ40 and Aβ42 levels. Linear regression
analysis revealed no correlation between plasma lev-274 K. Balakrishnan et al. / Body Fat and analysis of plasma amyloid-beta levels
Fig. 2. Positive correlations between FM, BMI and plasma Aβ42 levels A) Scattergram plot with trendline of fat mass vs plasma Aβ42 levels
(n =1 8 , r =0 .602, β =1 .176, P =0 .008). Bottom B) Scattergram plot with trendline of body mass index vs plasma Aβ42 levels (n =1 8 ,
r =0 .547, β =2 .349, P =0 .019).
els of Aβ40 and insulin (r = −0.204, β = −2.149,
P =0 .416). Although not signiﬁcant, a positive trend
was observed between plasma levels of Aβ42 and in-
sulin (r =0 .422, β =1 .857, P =0 .081, Fig. 3A).
However, BMI was signiﬁcantly correlated with in-
sulin (r =0 .735, β =0 .717, P =0 .001, Fig. 3B).
Overall these results indicate that in our cohort there is
a trend towards an association between plasma Aβ42
levels and insulin. Similar results were observed for
plasma levels of C-peptide, a molecule produced from
the same precursor molecule as insulin, proinsulin, is
more stable than insulin, and directly reﬂects insulin
secretion.
3.4. Association between Cardiovascular risk factors
and plasma levels of Aβ 42
We next investigated whether parameters used to
assess for risk of cardiovascular disease, including,
plasma levels of triglycerides, total cholesterol, low-
density lipoprotein(LDL) levels, high-densitylipopro-
tein (HDL), were correlated with plasma Aβ40 or 42
levels. Uponlinearregressionanalysis,thesemetabolic
parameters were not signiﬁcantly correlated with ei-
ther Aβ40 (Table 6) or Aβ42 levels (Table 7). How-
ever, although not signiﬁcant, an inverse trend was ob-
served between HDL and Aβ42 levels (r = −0.454,K. Balakrishnan et al. / Body Fat and analysis of plasma amyloid-beta levels 275
Fig. 3. Positive correlations between Insulin, C-Peptide and plasma Aβ42 levels and BMI. A) Scattergram plot with trendline of Insulin levels
vs plasma Aβ42 levels (n =1 8 , r =0 .422, β =1 .857, P =0 .081). B) Scattergram plot with trendline of body mass index vs Insulin levels
(n =1 8 , r =0 .735, β =0 .717, P =0 .001).
β = −20.277, P =0 .058; see Fig. 4). A neg-
ative correlation was found between HDL and BMI
(r = −0.590, β = −0.057, P =0 .010).
3.5. Associations of an inﬂammatory marker with
Aβ42 levels and BMI
We next investigated if there was an association be-
tween levels of the inﬂammatory marker CRP, used
to determine risk of cardiovascular disease and type 2
diabetes (reviewed in [24,69]), and plasma Aβ levels.
CRP levels did not, correlate with plasma Aβ40 levels
(r = −0.165, β = −7.558, P =0 .513). Although
a positive trend was observed, the levels of CRP did
not signiﬁcantly correlate with plasma Aβ42 levels,
(r =0 .425, β =8 .151, P =0 .079; see Fig. 5A). In-
terestingly,asigniﬁcantassociationwasfoundbetween
CRP and BMI (r =0 .831, β =3 .714, P =0 .000; see
Fig.5B).MultiplelinearregressionanalysisofCRPand
BMIwithplasmaAβ42levelsasthedependentvariable
was performed, revealing that the association between
CRP and Aβ42 remained non-signiﬁcant (P =0 .807;
see Table 8).
4. Discussion
Itis nowbecomingapparentthatriskfactorsforobe-
sity, such as type 2 diabetes and cardiovasculardisease
are also risk factors for Alzheimer’s disease. Direct276 K. Balakrishnan et al. / Body Fat and analysis of plasma amyloid-beta levels
Fig. 4. The Relationship Between HDLand Aβ42 Scattergram plot with trendline of HDLlevels vs plasma Aβ42 levels. Although not signiﬁcant
and inverse trend is observed between HDL and plasma Aβ42 levels (n =1 8 , r = −0.454, β = −20.277, P =0 .058).
Table 5
Multiple Linear Regression of BMI, Age, Sex, and APOE ε 4 Status
on Plasma Aβ42 Levels
Variable Unstandardised p-value
β Std. error
Age −0.311 0.256 0.247
Sex 20.326 8.422 0.031*
APOE ε 4 −4.26 7.39 0.574
BMI 3.75 0.998 0.002*
Age,female sex,presence ofanAPOEε4allele andbodymassindex
(BMI) were all included in a multiple linear regression analysis on
plasma Aβ42 levels. Signiﬁcance* was deﬁned as p<0.05.
Table 6
The Relationship Between Cardiovascular Risk Factors and Plasma
Aβ40 Levels
Variable Unstandardised p-value
rR 2 β Std. error
Cholesterol 0.046 0.002 1.69 9.253 0.857
Triglycerides −0.104 0.011 −3.648 8.703 0.681
HDL 0.017 0.000 1.778 26.646 0.948
LDL 0.165 0.027 7.268 11.245 0.528
Plasmacholesterol, triglyceride, high density lipoprotein (HDL),and
low density lipoprotein (LDL) levels were examined separately by
simple linear regression in relation to plasma Aβ40 levels. Signiﬁ-
cance* was deﬁned as p<0.05.
evidence for obesity as an AD risk factor has come
from one report which has shown that compared to
age-matched controls, individuals who developed AD
had a higher BMI, a measure of overweight and obe-
sity[23]. However,todateanassociationbetweenBMI
and plasma levels of Aβ, a protein that is implicated
in AD pathogenesis, has not been reported. In this
Table 7
The Relationship Between Cardiovascular Risk Factors and Plasma
Aβ42 Levels
Variable Unstandardised p-value
rR 2 β Std. error
Cholesterol 0.062 0.004 0.956 3.871 0.808
Triglycerides 0.104 0.011 1.528 3.644 0.680
HDL −0.454 0.206 −20.277 9.939 0.058
LDL 0.259 0.067 4.802 4.627 0.316
Plasmacholesterol, triglyceride, highdensity lipoprotein (HDL),and
low density lipoprotein (LDL) levels were examined separately by
simple linear regression in relation to plasma Aβ42 levels. Signiﬁ-
cance* was deﬁned as p<0.05.
Table 8
Multiple LinearRegression ofCRPandBMIonPlasmaAβ42Levels
Variable Unstandardised p-value
β Std. error
CRP −1.854 7.444 0.807
BMI 2.694 1.666 0.127
C-Reactive protein (CRP) and BMI were included in a multiple lin-
ear regression analysis with plasma Aβ42 levels as the dependent
variable. The association between CRP and Aβ42 remained non-
signiﬁcant.
studywe investigatedwhetherthere was an association
between BMI and plasma levels of Aβ40 and Aβ42.
Although BMI is the most commonly used mea-
surement of overweight and obesity, it does not take
into account the relative muscle mass of subjects [40]
Thus, the fat mass (FM) of subjects was also mea-
sured and correlated with plasma Aβ levels. The
percentage fat mass was assessed through bioelec-K. Balakrishnan et al. / Body Fat and analysis of plasma amyloid-beta levels 277
Fig. 5. The relationship between CRP levels and Aβ42. A) Scattergram plot with trendline of CRP levels vs plasma Aβ42 levels. Although not
signiﬁcant a positive trend is observed between CRP and plasma Aβ42 levels (n =1 8 , r =0 .452, β =8 .151, P =0 .079). (B) Scattergram
plot with trendline of CRP levels vs BMI shows a signiﬁcant correlation (r =0 .831, β =3 .714, P =0 .000).
trical impedance analysis. Although. bioelectrical
impedance is not as sensitive as dual-energy X-ray ab-
sorptiometry (DEXA), which measures fat mass, lean
body mass and bone mass, it is relatively cheap and
a reliable alternative. A very recent study in a large
cohortof 591 healthyadults showedthat data collected
from bioelectrical impedance correlated well with that
collectedfromDEXAwhensubjectswerewithinanor-
malbodyfat range[64],whichisthecase inthecurrent
study (FM 17.8%, BMI 23.5 Kg/m2).
Our data showed that a higher BMI and increased
FM were signiﬁcantly correlated with plasma levels of
the longer form of Aβ (Aβ42) and was independent
of age, sex, and the presence of an APOE ε 4 allele.
However, plasma levels of Aβ40, the shorter form of
Aβ, were not associated with increased BMI or FM.
This ﬁnding is of great interest as Aβ42 is considered
the more pathogenic species in AD and can rapidly
aggregate into oligomers which are now thought to be
the neurotoxic form of Aβ, rather than the ﬁbrillar
or plaque form (reviewed in [73]). Furthermore in-
creased plasma levels of Aβ42 (but not Aβ40), have278 K. Balakrishnan et al. / Body Fat and analysis of plasma amyloid-beta levels
been associated with an increased risk of AD [46].
Mayeux and colleagues [46] also reported in 530 el-
derly (>65 yrs) individuals, that plasma Aβ42 lev-
els, but not Aβ40 levels were inversely related to BMI
(r = −0.1, P =0 .05). Here, we report a stronger,
more signiﬁcant positive correlation between plasma
Aβ42 and both BMI (r =0 .547, P =0 .019) and
FM (r =0 .602, P =0 .008) which do not corrob-
orate the inverse correlation reported by Mayeux and
colleagues [46]). This could be explained by the age
differencesbetweenthe cohortsin thetwo studies. The
population used by Mayeux and colleagues [46] was
an elderly population, where BMI is generally lower
and may not reﬂect BMI at a younger age. In addition
the population used in the Mayeux study consisted of
normal controls (without dementia), patients clinically
diagnosed with AD (at baseline) and those that devel-
oped AD (after follow up) in which BMI levels were
found to be lower compared to those observed for the
control subjects.
Plasma Aβ42 levels have been shown to either re-
main similar to age matched controls, or decline after
the onset of the disease [46,50,67]. The ﬁndings from
ourstudiesandthosefromMayeuxandcolleagues[46]
indicate that investigations undertaken by each labo-
ratory correspond to evaluating associations between
BMI and plasma Aβ42 levels at different ages. The
positive association between BMI and plasma Aβ42
levelsshownbyourstudywas in ayoungerpopulation,
thusservingasapotentialriskfactorforAD.Thenega-
tiveassociationbetweenBMI andplasmaAβ42shown
by Mayeux and colleagues [46] was only obtained fol-
lowing the onset of the disease, which represents the
sequelae of the disease process.
The mechanism by which being overweight or obe-
sity triggers increased plasma Aβ42 levels is unclear,
and it is not known if the effects are a direct conse-
quence of increased adiposity, or indirectly mediated
through co-morbid states, such as diabetes or cardio-
vascular disease. To investigate this further, levels of
insulinweremeasuredinourcohortandcomparedwith
plasma Aβ42 levels to determine if there is an asso-
ciation. Although it did not reach statistical signiﬁ-
cance (most likely due to the small sample size), a pos-
itive trend was observed between plasma levels of in-
sulin and Aβ42. This result is consistent with previous
reports which showed that insulin infusion in healthy
adults resulted in increased CSF or plasma levels of
Aβ42 [75]. Insulin has been shown to increase the
trafﬁcking and extracellular secretion of Aβ [20]. Fur-
thermore, insulin has been shown to increase extra-
cellular Aβ levels by preventing Aβ degradation via
competitiveinhibitionoftheinsulindegradingenzyme,
(IDE) [16,37,38]. Thus the trend of increasing Aβ42
levels with increasing levels of insulin may be, in part,
due to a reduction in the degradation and clearance of
the Aβ peptide. Of particular note is the signiﬁcant
positive correlation that was observed between insulin
and BMI, which is consistent with other studies [2,12],
andsuggests that the link betweenBMI and Aβ42 may
be mediated to a certain extent through the effects of
insulin, both on the increased production, and reduced
degradation of Aβ.
Another potential mechanism by which being over-
weight and obesity may inﬂuence Aβ levels may be
through changes to the lipid and cholesterol proﬁle.
High plasma cholesterol, triglyceride, and LDL lev-
els, as well as low plasma HDL levels have long been
known to be associated with overweight and obesity,
and have all been identiﬁed as signiﬁcant risk factors
for AD [36,56]. Our study did not show signiﬁcant as-
sociations between levels of cholesterol, triglycerides
or LDL and Aβ levels. Increasing the number of par-
ticipantsinthestudymayshowsigniﬁcantassociations
between these parameters. Nevertheless, our study re-
vealed a negative trend between HDL and Aβ42 levels
and a signiﬁcant correlation between BMI and HDL
levels. Plasma HDL has been shown to be lower in
patients with AD and is highly correlated with lower
cognitive scores from AD individuals [36,51]. Fur-
thermore, HDL has been shown to interact with Aβ
in plasma [52,53] and can regulate Aβ aggregation,
degradation and toxicity [9,13,57] suggesting possible
mechanisms by which HDL could modify the risk of
developing AD. These cardiovascular risk factors may
also contribute to AD through their modulatory effects
on the proteolytic processing of the parent molecule to
Aβ, the amyloid β protein precursor (AβPP) [1,62],
generating more Aβ42.
It is interesting to note that obesity, cardiovascular
disease, type 2 diabetes and AD all have inﬂammatory
processes which play a role in disease process. We
therefore investigated in our cohort whether there was
an association between BMI, Aβ levels and the lev-
els of CRP, a sensitive and stable marker of inﬂamma-
tion [63]. Elevated levels of CRP have been associated
withincreasedBMI,(measureofobesity),serumlipids
(indicatorof cardiovasculardisease risk) and increased
fasting glucose levels (indicator of diabetes risk) [10,
17,25,30,34,70]. In AD, an inﬂammatory state has
been well characterised, however CRP has yet to be
associated with levels of Aβ40 or Aβ42.K. Balakrishnan et al. / Body Fat and analysis of plasma amyloid-beta levels 279
Although not signiﬁcant, an increasing trend in
plasma Aβ42 levels with increasing levels of CRP
was shown in our study. However, as previously re-
ported [21,33,61,66],we found that increased levels of
BMI were strongly associated with increases in CRP
levels (r =0 .831, β =3 .714, P =0 .000). Further-
more, elevated levels of other inﬂammatory markers
including interleukin 1 and 6 (IL-1, 6), tumour necro-
sis factor α and β (TNFα,β) have been reported in
obese individuals [4,11,74]. Taken together, these data
suggest that obesity and overweight may be associ-
ated with inﬂammatory processes. Some of these in-
ﬂammatory markers including IL-1β, TNF-α and IL-
6 have been shown to regulate the production of Aβ,
particularly Aβ42 [5,43,59]. In light of these studies,
ourresultsshowingapositivecorrelationbetweenBMI
and FM with plasma levels of Aβ42, suggest that this
correlation may have associations with inﬂammatory
processes. Furthermore, evidence exists that shows
weightloss is associatedwith afall in cytokineproduc-
tion [11,31]. Thus, it may be plausible that by loos-
ing weight, the risk of AD may be reduced in a man-
ner somewhat analogous to the effect of non-steroidal
anti-inﬂammatory drugs on AD risk [29,48,78].
This study is the ﬁrst to report a positive association
betweenplasmaAβ42levelsandthedirectmeasuresof
overweightandobesity,BMIandFM,innon-demented
adults. Although larger longitudinal studies are re-
quired, this pilot study suggests that elevated body fat
may not only predispose individuals to cardiovascular
disease, type 2 diabetes and associated inﬂammatory
processes, but also to AD. Furthermore, these results
suggest that by maintaining body weight at a normal
level, individuals may be able to reduce their risk of
developing AD.
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